Literature DB >> 18948947

Somatic mutations affect key pathways in lung adenocarcinoma.

Li Ding1, Gad Getz, David A Wheeler, Elaine R Mardis, Michael D McLellan, Kristian Cibulskis, Carrie Sougnez, Heidi Greulich, Donna M Muzny, Margaret B Morgan, Lucinda Fulton, Robert S Fulton, Qunyuan Zhang, Michael C Wendl, Michael S Lawrence, David E Larson, Ken Chen, David J Dooling, Aniko Sabo, Alicia C Hawes, Hua Shen, Shalini N Jhangiani, Lora R Lewis, Otis Hall, Yiming Zhu, Tittu Mathew, Yanru Ren, Jiqiang Yao, Steven E Scherer, Kerstin Clerc, Ginger A Metcalf, Brian Ng, Aleksandar Milosavljevic, Manuel L Gonzalez-Garay, John R Osborne, Rick Meyer, Xiaoqi Shi, Yuzhu Tang, Daniel C Koboldt, Ling Lin, Rachel Abbott, Tracie L Miner, Craig Pohl, Ginger Fewell, Carrie Haipek, Heather Schmidt, Brian H Dunford-Shore, Aldi Kraja, Seth D Crosby, Christopher S Sawyer, Tammi Vickery, Sacha Sander, Jody Robinson, Wendy Winckler, Jennifer Baldwin, Lucian R Chirieac, Amit Dutt, Tim Fennell, Megan Hanna, Bruce E Johnson, Robert C Onofrio, Roman K Thomas, Giovanni Tonon, Barbara A Weir, Xiaojun Zhao, Liuda Ziaugra, Michael C Zody, Thomas Giordano, Mark B Orringer, Jack A Roth, Margaret R Spitz, Ignacio I Wistuba, Bradley Ozenberger, Peter J Good, Andrew C Chang, David G Beer, Mark A Watson, Marc Ladanyi, Stephen Broderick, Akihiko Yoshizawa, William D Travis, William Pao, Michael A Province, George M Weinstock, Harold E Varmus, Stacey B Gabriel, Eric S Lander, Richard A Gibbs, Matthew Meyerson, Richard K Wilson.   

Abstract

Determining the genetic basis of cancer requires comprehensive analyses of large collections of histopathologically well-classified primary tumours. Here we report the results of a collaborative study to discover somatic mutations in 188 human lung adenocarcinomas. DNA sequencing of 623 genes with known or potential relationships to cancer revealed more than 1,000 somatic mutations across the samples. Our analysis identified 26 genes that are mutated at significantly high frequencies and thus are probably involved in carcinogenesis. The frequently mutated genes include tyrosine kinases, among them the EGFR homologue ERBB4; multiple ephrin receptor genes, notably EPHA3; vascular endothelial growth factor receptor KDR; and NTRK genes. These data provide evidence of somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers--including NF1, APC, RB1 and ATM--and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B. The observed mutational profiles correlate with clinical features, smoking status and DNA repair defects. These results are reinforced by data integration including single nucleotide polymorphism array and gene expression array. Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment.

Entities:  

Mesh:

Year:  2008        PMID: 18948947      PMCID: PMC2694412          DOI: 10.1038/nature07423

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  50 in total

1.  TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.

Authors:  Florence Le Calvez; Anush Mukeria; Jay D Hunt; Olaf Kelm; Rayjean J Hung; Philippe Tanière; Paul Brennan; Paolo Boffetta; David G Zaridze; Pierre Hainaut
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

2.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors.

Authors:  Jonathan R Pollack; Therese Sørlie; Charles M Perou; Christian A Rees; Stefanie S Jeffrey; Per E Lonning; Robert Tibshirani; David Botstein; Anne-Lise Børresen-Dale; Patrick O Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-24       Impact factor: 11.205

3.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53.

Authors:  N H Chehab; A Malikzay; M Appel; T D Halazonetis
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

4.  p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study.

Authors:  Steven A Ahrendt; Yingchuan Hu; Martin Buta; Michael P McDermott; Nicole Benoit; Stephen C Yang; Li Wu; David Sidransky
Journal:  J Natl Cancer Inst       Date:  2003-07-02       Impact factor: 13.506

5.  APC mutations are infrequent but present in human lung cancer.

Authors:  Hiroko Ohgaki; Johan M Kros; Yoshikazu Okamoto; Ariana Gaspert; Hervé Huang; Michael O Kurrer
Journal:  Cancer Lett       Date:  2004-04-30       Impact factor: 8.679

6.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

7.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

8.  Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.

Authors:  Montserrat Sanchez-Cespedes; Paola Parrella; Manel Esteller; Shuji Nomoto; Barry Trink; James M Engles; William H Westra; James G Herman; David Sidransky
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

9.  Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma.

Authors:  Itaru Sonoda; Issei Imoto; Jun Inoue; Tatsuhiro Shibata; Yutaka Shimada; Koei Chin; Masayuki Imamura; Teruo Amagasa; Joe W Gray; Setsuo Hirohashi; Johji Inazawa
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  1268 in total

Review 1.  Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

Authors:  S A Kono; L E Heasley; R C Doebele; D R Camidge
Journal:  Curr Cancer Drug Targets       Date:  2012-02       Impact factor: 3.428

2.  Pan-cancer analysis of expressed somatic nucleotide variants in long intergenic non-coding RNA.

Authors:  Travers Ching; Lana X Garmire
Journal:  Pac Symp Biocomput       Date:  2018

Review 3.  Practicing pathology in the era of big data and personalized medicine.

Authors:  Jiang Gu; Clive R Taylor
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014-01

4.  Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients.

Authors:  Youngwook Kim; Peter S Hammerman; Jaegil Kim; Ji-ae Yoon; Yoomi Lee; Jong-Mu Sun; Matthew D Wilkerson; Chandra Sekhar Pedamallu; Kristian Cibulskis; Yeong Kyung Yoo; Michael S Lawrence; Petar Stojanov; Scott L Carter; Aaron McKenna; Chip Stewart; Andrey Y Sivachenko; In-Jae Oh; Hong Kwan Kim; Yong Soo Choi; Kwhanmien Kim; Young Mog Shim; Kyu-Sik Kim; Sang-Yun Song; Kook-Joo Na; Yoon-La Choi; D Neil Hayes; Jhingook Kim; Sukki Cho; Young-Chul Kim; Jin Seok Ahn; Myung-Ju Ahn; Gad Getz; Matthew Meyerson; Keunchil Park
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

5.  Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells.

Authors:  Imoh S Okon; Kathleen A Coughlan; Ming-Hui Zou
Journal:  J Biol Chem       Date:  2013-11-27       Impact factor: 5.157

6.  Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma.

Authors:  Kristina Y Aguilera; Huocong Huang; Wenting Du; Moriah M Hagopian; Zhen Wang; Stefan Hinz; Tae Hyun Hwang; Huamin Wang; Jason B Fleming; Diego H Castrillon; Xiaomei Ren; Ke Ding; Rolf A Brekken
Journal:  Mol Cancer Ther       Date:  2017-09-01       Impact factor: 6.261

7.  Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma.

Authors:  Marie Cumberbatch; Ximing Tang; Garry Beran; Sonia Eckersley; Xin Wang; Rebecca P A Ellston; Simon Dearden; Sabina Cosulich; Paul D Smith; Carmen Behrens; Edward S Kim; Xinying Su; Shuqiong Fan; Neil Gray; David P Blowers; Ignacio I Wistuba; Chris Womack
Journal:  Clin Cancer Res       Date:  2013-11-27       Impact factor: 12.531

8.  Genetic susceptibility to interstitial pulmonary fibrosis in mice induced by vanadium pentoxide (V2O5).

Authors:  Dianne M Walters; Kevin M White; Ushma Patel; Martin J Davis; Roberta M Veluci-Marlow; Solomon Raju Bhupanapadu Sunkesula; James C Bonner; Jessica R Martin; Wes Gladwell; Steven R Kleeberger
Journal:  FASEB J       Date:  2013-11-27       Impact factor: 5.191

Review 9.  DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.

Authors:  Henning Willers; Liliana Gheorghiu; Qi Liu; Jason A Efstathiou; Lori J Wirth; Mechthild Krause; Cläre von Neubeck
Journal:  Semin Radiat Oncol       Date:  2015-05-14       Impact factor: 5.934

10.  ZWINT is the next potential target for lung cancer therapy.

Authors:  Fang Peng; Qiang Li; Shao-Qing Niu; Guo-Ping Shen; Ying Luo; Ming Chen; Yong Bao
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-14       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.